HDM1005

2 papers7 findings

C, W, M, H: cells, worms or flies, mice, humans. Dark: independent labs found the same change there. Light: one lab or one study. Outline: nothing yet.

Labs are independent when their papers share no last author and no institution.

Against: findings that point the other way from most findings on the same outcome.

On aging: the drug’s trials ARN judged to be about aging, of every trial that tests it for any use.

No results posted: trials that ended more than a year ago with no results on ClinicalTrials.gov and no paper in ARN’s record.

Company ties: findings with an author at a company, or from a paper whose competing-interests statement declares ties to one.

2 independent labs

Human trial2

Outcomes

Body weight

downin humans2

2 studies

HDM1005 decreases body weight in humans (-7.38% to -13.32% vs -2.45% placebo (all p<0.0001)).
“the body weight reduction from baseline for HDM1005 groups of 0.5 mg, 1.0 mg, 2.0 mg, and 4.0 mg were 7.38%, 9.61%, 13.21%, and 13.32%, respectively vs placebo 2.45% (all p<0.0001).”
Human trial22 weeksn = 243
Efficacy and Safety of Dual GLP-1/GIP Receptor Agonist HDM1005 in Obese Participants without Diabetes: A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Trial
ADA Scientific Sessions 2026 abstract5 Jun 2026
HDM1005 decreases body weight in humans (4.79-7.76 kg (6.12%-10.29%) vs 3.13 kg (3.71%) in placebo).
“In MAD, the mean reductions in body weight on D29 ranged from 4.79-7.76 kg (6.12%-10.29%) across 0.5-4.0 mg groups versus 3.13kg (3.71%) in placebo”
Human trialMAD cohort, across 0.5-4.0 mg groups4 weeks
Safety, Tolerability, Pharmacokinetics (PK), and Pharmacodynamics (PD) of a Dual GLP-1/GIP Receptor Agonist (HDM1005)—A Phase I, Randomized, Double-Blind, Placebo-Controlled, Single and Multiple Dose-Escalation Study
ADA Scientific Sessions 2025 abstract13 Jun 2025